SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001214659-21-003635
Filing Date
2021-03-30
Accepted
2021-03-30 17:41:42
Documents
2
Period of Report
2021-03-26

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT marketforms-52137.html 3  
1 PRIMARY DOCUMENT marketforms-52137.xml 3 2409
2 POA DOCUMENT poa.htm EX-24 3242
  Complete submission text file 0001214659-21-003635.txt   7063
Mailing Address C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Business Address
Sharp Shalini (Reporting) CIK: 0001377202 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-35921 | Film No.: 21788650

Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Issuer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences